John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

Selective modulation of the apoptotic machinery has been the goal of oncology developers for more than two decades. The field continues to face special challenges. Many of the targets are ...

AbbVie says that navitoclax is a first-in-class therapy, targeting a different part of the BCL-2 pathway to Roche-partnered Venclexta (venetoclax), which is approved to treat chronic lymphocytic ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

Developed by Ascentage Pharma, lisaftoclax is a novel orally available Bcl-2 inhibitor with clinical benefits for an array of hematologic malignancies and solid tumors. At this year's ASH Annual ...

Identification of six cancer susceptibility genes offers new insights into genetic risk factors, potentially enhancing early ...

Pathway 2 comprises five role profiles. They set out the levels of contribution by academic staff whose roles are focused wholly or mainly on research-related activity. These role profiles were ...

although alternative methods of targeting these pathways may be effective. MEK inhibitors form the backbone of multiple regimens entering clinical trials and are being combined with BCL-XL ...

Mission Statement: Evidence-based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research ...

The MSc Education (Open Pathway) allows you to design your own programme of study based on your areas of interest, rather than choosing one subject area from our specialist pathways. Units can be ...

Bcl-2 levels decreased with SLE sera exposure and ... protein levels and AMPK activity to normal levels). The SIRT3-AMPK ...